INNOVATION PHARMACEUTICALS INC.
July 15, 2020
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Innovation Pharmaceuticals Inc. |
|
| Registration Statement on Form S-3 (File No. 333-239817) |
|
| Filed July 10, 2020 |
|
| Request for Acceleration of Effective Date |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Innovation Pharmaceuticals Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-239817) and declare the Registration Statement effective as of Friday, July 17, 2020, at 4:00 p.m., Eastern time, or as soon as practicable thereafter.
Please contact the undersigned at (978) 921-4125, or David Crandall of Hogan Lovells US LLP at (303) 454‑2449, with any questions. Also, please notify Mr. Crandall when this request for acceleration has been granted.
Very truly yours, | |||
|
|
| |
| Innovation Pharmaceuticals Inc. |
| |
By: | /s/ Leo Ehrlich | ||
| Name: | Leo Ehrlich | |
Title: | Chief Executive Officer | ||
cc: David R. Crandall, Hogan Lovells US LLP
301 Edgewater Place – Suite 100, Wakefield, MA 01880 Phone: (978) 921-4125